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Summary The expression of the drug resistance (DR) mediators P-glycoprotein (P-gp) and the metallothioneins (MT) was assessed
immunohistochemically in biopsy material from patients with high-grade malignant osteosarcoma (OS). No significant difference was found in
survival rate between expressors of both P-gp and MT and non-expressors. Thus, it was concluded that lack of expression of these two drug
resistance-related proteins does not appear to confer any advantage in terms of patient survival in osteosarcoma.
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Failure to respond to, or relapse from, drug therapy are among the
most common causes ofdeath in patients with osteosarcoma (OS).
Tumour unresponsiveness to drug therapy may be related to many
factors. The most frequently described model of drug resistance
is the P-glycoprotein (P-gp)-specific multiple-drug resistance
(MDR) gene phenotype (Juliano and Ling, 1976). Increased levels
of P-gp are thought to confer MDR to tumour cells by decreasing
the net intracellular accumulation ofunrelated lipophilic cytotoxic
agents, such as doxorubicin and vincristine (Weinstein et al, 1990),
which are commonly used in treatment regimens for high-grade
malignant OS. Results from earlier studies carried out on OS have
been conflicting. While some have shown a correlation between P-
gp expression at biopsy, and response to therapy (Chan et al, 1991;
Wunder et al, 1993), other groups have shown that it is possible
for OS cells to be P-gp negative, but still be drug resistant
(Shnyder et al, 1994; Kandel et al, 1995).
Various mechanisms for drug resistance due to the exclusion
from cells ofcisplatinum, which is also commonly used in therapy
for OS, have also been proposed (Richon et al, 1987; Andrews and
Howell, 1990). One such mechanism proposes the involvement
of metallothioneins (MTs), which are intracellular cytoplasmic
proteins containing high amounts of thiol groups as well as being
rich in cysteine. These thiol groups are able to bind to several cyto-
toxic agents containing heavy metals (Thiele et al, 1986), such as
cisplatinum. MTs appear to have a physiological role in the
absorption, transport and metabolism of important trace metals, as
well as a role in heavy metal detoxification. MTs have also been
shown to affect the cellular sensitivity to cisplatinum (Bahnson
et al, 1991; Kasahara et al, 1991; Chin et al, 1993; Kondo et al,
1995). No previous studies have reported on MT expression in OS.
In this study, the expression of P-gp and MT was assessed
immunohistochemically in biopsy material from patients with
clinically diagnosed high-grade malignant OS, and the expression
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of these molecules was statistically analysed with respect to
patient survival data (over 5 years) to determine whether there
were any correlations between expression and resistance to
doxorubicin and cisplatinum.
MATERIALS AND METHODS
Formalin-fixed, paraffin wax-embedded biopsy material from 18
patients with clinically diagnosed high-grade malignant OS (for
whom 5-year post-surgical follow-up data were known) was used.
When patients had died during the 5-year time period, these
patients were selected so that death was diagnosed as being
tumour related. All patients were subjected to chemotherapy
protocols including doxorubicin and cisplatinum.
Sections were de-waxed and rehydrated through into phosphate-
buffered saline (PBS, pH 7.4; Oxoid) before being subjected to an
immunofluorescence procedure. Adjacent sections were used for
the two antibodies. Afterblocking with normal rabbit serum (1:20)
(Dako, High Wycombe, UK), sections were incubated for 1 h at
room temperature in the primary monoclonal antibody, either
C219 (anti-human P-gp marker, CIS (UK), High Wycombe, UK)
or E9 [anti-horse (human cross-reactive) MT isoforms 1 and 2
marker, Dako]. Both antibodies were used at a protein concentra-
tion of 5 ,ug ml-'. Sections were then washed in PBS, and FITC-
conjugated rabbit anti-mouse secondary antibody (Dako) added
for I h. After subsequent washes in PBS, sections were incubated
with the DNA/RNA counterstain propidium iodide (Molecular
Probes, San Francisco, CA, USA) at a concentration of 1 ,ug ml-,
and then washed thoroughly in water and mounted in glycerol
containing the anti-fading agent DABCO (1,4-diazabicyclo-
[2.2.2]octane) (Sigma, Poole, UK). Negative control slides had
murine non-immune IgGs instead of the primary antibody. As a
positive control, sections of normal human dermis, in which seba-
ceous glands have been shown to be positive for P-gp (Van der
Valk et al, 1990), were used. Assessment ofimmunopositivity was
carried out using confocal laser scanning microscopy (Molecular
Dynamics Sarastro 2000). Specimens were scanned using a 25
mW argon ion laser with appropriate excitation and emission
filters for the simultaneous scanning of fluorescein (488/515-545
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Figure 1 (A and B) Low- and high-magnification confocal images showing areas of osteosarcoma tissue with immunostaining for the C219 antibody. Positivity
is seen as granules overlying cell membranes (arrows). Cell nuclei counterstained with propidium iodide. Bar length: A, 10 rm; B, 5 pm. (C and D) Low- and
high-magnification confocal images showing areas of osteosarcoma tissue with immunostaining for the E9 antibody. Positivity is seen as granules overlying cell
membranes (arrows). Cell nuclei counterstained with propidium iodide. Bar length: C, 10 im; D, 5 gm
nm) and propidium iodide (488/570 nm). To reduce photo-
bleaching of fluorescence, the laser output was attenuated using a
30% neutral density filter. Specimens were examined using a 40 x
oil immersion objective lens, and a 50 tm confocal aperture
rejected out-of-focus fields from the emitted fluorescent light.
Optical sections were collected as 512 x 512 pixel images and
analysed using Molecular Dynamics 'Imagespace' volume
rendering software running on a Silicon Graphics UNIX work-
station. Projections were made using a look-depth reconstruction
method. Using this method, optical section layers are added
together and deeper layers are attenuated proportionally to their
distance from the viewer before the addition to the reconstruction.
Section series were filtered using 3D Gaussian (smoothing or
noise removal) or 3D gradient (edge definition) filters. Hard
copies of these images were subsequently produced on a Shinko
CHC-S446i dye sublimation colour printer. One thousand cells in
total were counted for each biopsy.
Statistical analysis ofthe disease-free survival plots was carried
out using Kaplan-Meier product limit analysis, and log-rank
analysis was used to calculate P-values.
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Figure 2 (A) Kaplan-Meier survival curves in terms of expression of P-
glycoprotein assessed using the C219 antibody. (B) Kaplan-Meier survival
curves in terms of expression of metallothionein assessed using the E9
antibody. S(t) = cumulative survival at time t
RESULTS
C219 and E9 positivity was visualized as particulate fluorescence
overlying cell membranes (Figure 1A-D). Ofthe 18 patients, eight
had C219-positive cells (range 0.56-6.98%, median 2.16%) and
11 had MT-positive cells (range 0.63-11.83%, median 5.41Y%). Six
patients were positive for both antibodies. The propidium iodide
positivity was mainly overlying the nucleus, although some cyto-
plasmic staining was observed, which is likely to be the product of
non-specific mRNA staining.
Statistical analysis of the Kaplan-Meier survival curves for
C219 (Figure 2A) and E9 (Figure 2B) expressing and non-
expressing patients showed that there were no significant differ-
ences in survival rate between expressors and non-expressors
(P = 0.81 for C219; P = 0.88 for E9). No significant differences
were seen when low and high percentages ofexpression (i.e. < 5%
or > 5% of cells) were analysed. In addition, expression of both
P-gp and MT phenotypes had no significance compared with
expression ofjust one (or no) phenotype.
DISCUSSION
The aims of this study were to determine whether there was any
correlation between expression of two drug resistance phenotypes,
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P-gp and MT, and the response of patients with high-grade OS to
chemotherapy containing agents whose efficacy is hindered by the
P-gp and MT mechanisms.
Using the confocal laser scanning microscope and a fluorescent
nuclear counterstain, it was possible to clearly distinguish cells
showing positivity to the C219 and E9 antibodies. However, it was
not possible to colocalize the antibodies on the same section of
tissue along with a nuclear counterstain, and thus adjacent sections
of biopsy had to be used, ensuring that virtually the same cell
populations were scrutinized for both antibodies.
In a previous study (Shnyder et al, 1994), we found that there
was a decrease in the number of P-gp-positive cells in analysis of
tissue post chemotherapy compared with pretreatment biopsy
tissue, and we postulated that the P-gp-positive cells were being
removed during therapy by agents that could circumvent this type
of resistance, e.g. cisplatinum. We further suggested that MT was
one mechanism of resistance for cisplatinum. In this study, we
have demonstrated that there is no correlation between protein
expression before chemotherapy and patient survival for both
expression of the P-gp and the MT phenotypes, with lack of
expression of either or both P-gp and MT not appearing to confer
any advantage in terms of patient survival in patients with OS.
These data would suggest that other mechanisms of MDR play a
role in osteosarcoma.
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